Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04377659 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04377659: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04377659 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04377659, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
Interventions
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2022-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04377659
The ClinicalTrials.gov registry entry for NCT04377659 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tocilizumab is the first listed.
NCT04377659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04377659 about?
NCT04377659 is a clinical study titled "Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection". The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
What is the current status of trial NCT04377659?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-05-01. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT04377659?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT04377659?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.